Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 1
1995 1
1996 3
1997 2
1998 2
1999 3
2001 1
2002 1
2003 1
2004 2
2005 3
2006 3
2008 4
2009 1
2010 3
2011 7
2012 3
2013 1
2014 1
2015 3
2016 2
2017 3
2018 5
2019 4
2020 3
2021 4
2022 2
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Risks for infection in patients with myelodysplasia and acute leukemia.
Pagano L, Caira M. Pagano L, et al. Curr Opin Infect Dis. 2012 Dec;25(6):612-8. doi: 10.1097/QCO.0b013e328358b000. Curr Opin Infect Dis. 2012. PMID: 22964946 Review.
PURPOSE OF REVIEW: The aim of the present review is to analyze the main parameters that may influence the onset of bacterial, fungal and viral infections in patients with myelodysplastic syndromes, acute myeloid leukemia and acute lymphoid le …
PURPOSE OF REVIEW: The aim of the present review is to analyze the main parameters that may influence the onset of bacterial, fungal and vir …
GATA2 deficiency.
Hsu AP, McReynolds LJ, Holland SM. Hsu AP, et al. Curr Opin Allergy Clin Immunol. 2015 Feb;15(1):104-9. doi: 10.1097/ACI.0000000000000126. Curr Opin Allergy Clin Immunol. 2015. PMID: 25397911 Free PMC article. Review.
Disease-associated mutations in intronic regulatory elements or variations within the 5' leader exons indicate that regulation of GATA2 is critical. Those with GATA2 mutations are at high risk for myelodysplasia, cytogenetic abnormalities, acute myeloid le …
Disease-associated mutations in intronic regulatory elements or variations within the 5' leader exons indicate that regulation of GATA2 is c …
Incidence and predisposing factors of infection in patients treated with hypomethylating agents.
Kirkizlar TA, Kirkizlar O, Demirci U, Umut A, Iflazoglu H, Umit EG, Demir AM. Kirkizlar TA, et al. Leuk Res. 2023 Apr;127:107043. doi: 10.1016/j.leukres.2023.107043. Epub 2023 Feb 15. Leuk Res. 2023. PMID: 36801588
Hence, we aimed to reveal the frequence of infections, predisposing factors of infection and to analyse infection attributable mortality in patients with high-risk MDS, CMML and AML who received hypomethylating agents in our center where routine …
Hence, we aimed to reveal the frequence of infections, predisposing factors of infection and to analyse infection attri …
Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
Tey A, Shaw B, Cardamone L, Shepherd S, Paul E, Rogers B, Shortt J. Tey A, et al. Eur J Haematol. 2021 Aug;107(2):181-189. doi: 10.1111/ejh.13631. Epub 2021 May 27. Eur J Haematol. 2021. PMID: 33829584
The rate of invasive fungal infection (IFI) in patients with myelodysplasia (MDS) and acute myeloid leukemia (AML) receiving 5-azacytidine is incompletely defined and published recommendations for mold-active fungal prophylaxis in such patien …
The rate of invasive fungal infection (IFI) in patients with myelodysplasia (MDS) and acute myeloid leukemia …
Severe congenital neutropenia.
Welte K, Zeidler C, Dale DC. Welte K, et al. Semin Hematol. 2006 Jul;43(3):189-95. doi: 10.1053/j.seminhematol.2006.04.004. Semin Hematol. 2006. PMID: 16822461 Review.
Adverse events include mild splenomegaly, osteoporosis, and malignant transformation into myelodysplasia (MDS)/leukemia. If and how G-CSF treatment impacts on these adverse events is not fully understood. In recent analyses the influence of the G-CSF dose required t …
Adverse events include mild splenomegaly, osteoporosis, and malignant transformation into myelodysplasia (MDS)/leukemia. If an …
How to approach neutropenia.
Boxer LA. Boxer LA. Hematology Am Soc Hematol Educ Program. 2012;2012:174-82. doi: 10.1182/asheducation-2012.1.174. Hematology Am Soc Hematol Educ Program. 2012. PMID: 23233578 Review.
Neutropenia arising as a result of underlying hematologic disorders is far more significant. Such a patient may be at risk for infectious complications and will likely require a thorough investigation. ...Elucidation of the multiple genetic defects have provided ins …
Neutropenia arising as a result of underlying hematologic disorders is far more significant. Such a patient may be at risk for …
Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor.
Dale DC, Bolyard AA, Shannon JA, Connelly JA, Link DC, Bonilla MA, Newburger PE. Dale DC, et al. Blood Adv. 2022 Jul 12;6(13):3861-3869. doi: 10.1182/bloodadvances.2021005684. Blood Adv. 2022. PMID: 35476051 Free PMC article.
This report summarizes findings from more than 16 000 patient-years of prospective observations for patients with congenital and acquired SCN. We observed that adverse outcomes depend on the underlying etiology. Myelodysplasia (MDS) and acute myeloid …
This report summarizes findings from more than 16 000 patient-years of prospective observations for patients with congenital a …
Treatment of Low-Blast Count AML using Hypomethylating Agents.
De Bellis E, Fianchi L, Buccisano F, Criscuolo M, Maurillo L, Cicconi L, Brescini M, Del Principe MI, Di Veroli A, Venditti A, Amadori S, Arcese W, Lo-Coco F, Voso MT. De Bellis E, et al. Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017045. doi: 10.4084/MJHID.2017.045. eCollection 2017. Mediterr J Hematol Infect Dis. 2017. PMID: 28698788 Free PMC article. Review.
In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid leukemia (AML) from 30% to 20%, eliminating the RAEB-t subtype of myelodysplastic syndromes (MDS). ...The role of these agents has a …
In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid …
Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting.
Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, Saito R, Konishi A, Hotta M, Yoshimura H, Ishii K, Ito T, Nomura S. Nakaya A, et al. Oncol Lett. 2020 Feb;19(2):1317-1321. doi: 10.3892/ol.2019.11225. Epub 2019 Dec 18. Oncol Lett. 2020. PMID: 31966063 Free PMC article.
Patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA) have exhibited improved overall survival. ...However, the present study did not identify any significant associations between patient characteristics and response to AZA. I …
Patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA) have exhibited improved overall surviva …
The promise of novel treatments for severe chronic neutropenia.
Dale DC, Bolyard AA, Makaryan V. Dale DC, et al. Expert Rev Hematol. 2023 Jul-Dec;16(12):1025-1033. doi: 10.1080/17474086.2023.2285987. Epub 2023 Dec 18. Expert Rev Hematol. 2023. PMID: 37978893 Review.
In the early days of G-CSF therapy, there were concerns that it might somehow overstimulate the bone marrow and cause myelodysplasia (MDS) or acute myeloid leukemia (AML). Detailed research records from the Severe Chronic Neutropenia International Registry (S …
In the early days of G-CSF therapy, there were concerns that it might somehow overstimulate the bone marrow and cause myelodysplasia …
71 results